Preventive effects of enzyme-treated rice fiber in a restraint stress-induced irritable bowel syndrome model

International Journal of Molecular Medicine

Volumn 25, Issue 4, 2010, Pages 547-555

  Kanauchi, Osamu ^a   Mitsuyama, Keiichi ^b   Komiyama, Yutaka ^a   Yagi, Minoru ^b   Andoh, Akira ^b   Sata, Michio ^b  

^a KIRIN HOLDINGS CO LTD   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Allodynia; Irritable bowel syndrome; Microbiota; Prebiotics; Serotonin; Short chain fatty acids

Indexed keywords

AMYLASE; BUTYRIC ACID; CARBOXYLIC ACID; CYTOKINE INDUCED NEUTROPHIL CHEMOATTRACTANT; CYTOKINE INDUCED NEUTROPHIL CHEMOATTRACTANT 1; HEMICELLULOSE; PREBIOTIC AGENT; SEROTONIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; COLON MUCOSA; COLON SECRETION; CONTROLLED STUDY; DIETARY FIBER; DRUG POTENCY; EUBACTERIUM LIMOSUM; FECES; FOOD INTAKE; IMMOBILIZATION STRESS; IRRITABLE COLON; LACTOBACILLUS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RICE BRAN;

AMYLASES; ANIMALS; BODY WEIGHT; CARBOXYLIC ACIDS; CHEMOKINE CXCL1; DIETARY FIBER; DISEASE MODELS, ANIMAL; FECES; FEEDING BEHAVIOR; INTESTINAL MUCOSA; IRRITABLE BOWEL SYNDROME; MALE; ORYZA SATIVA; PAIN THRESHOLD; RATS; RATS, SPRAGUE-DAWLEY; RESTRAINT, PHYSICAL; SEROTONIN; SOLUBILITY; STRESS, PHYSIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77749273865     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000376     Document Type: Article

References (46)

1. Spiller R: Clinical update: irritable bowel syndrome. Lancet 369: 1586-1588, 2007.
2. Spiller R, Aziz Q, Creed F, et al: Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 56: 1770-1798, 2007.
3. Talley NJ: Pharmacologic therapy for the irritable bowel syndrome. Am J Gastroenterol 98: 750-758, 2003.
4. Kristjansson G, Venge P, Wanders A, Loof L and Hallgren R: Clinical and subclinical intestinal inflammation assessed by the mucosal patch technique: studies of mucosal neutrophil and eosinophil activation in inflammatory bowel diseases and irritable bowel syndrome. Gut 53: 1806-1812, 2004.
5. Langhorst J, Junge A, Rueffer A, et al: Elevated human betadefensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome. Am J Gastroenterol 104: 404-410, 2009.
6. + blood T lymphocytes in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 3: 980-986, 2005.
7. Schoepfer AM, Schaffer T, Seibold-Schmid B, Muller S and Seibold F: Antibodies to flagellin indicate reactivity to bacterial antigens in IBS patients. Neurogastroenterol Motil 20: 1110-1118, 2008.
8. Bercik P, Verdu EF and Collins SM: Is irritable bowel syndrome a low-grade inflammatory bowel disease? Gastroenterol Clin North Am 34: 235-245, vi-vii, 2005.
9. Burgmann T, Clara I, Graff L, et al: The Manitoba Inflammatory Bowel Disease Cohort Study: prolonged symptoms before diagnosis - how much is irritable bowel syndrome? Clin Gastroenterol Hepatol 4: 614-620, 2006.
10. Quigley EM: Irritable bowel syndrome and inflammatory bowel disease: interrelated diseases? Chin J Dig Dis 6: 122-132, 2005.
11. Camilleri M: Probiotics and irritable bowel syndrome: rationale, putative mechanisms, and evidence of clinical efficacy. J Clin Gastroenterol 40: 264-269, 2006.
12. Floch MH: Probiotics, Irritable Bowel Syndrome, and Inflammatory Bowel Disease. Curr Treat Options in Gastroenterol 6: 283-288, 2003.
13. Kanauchi O, Mitsuyama K, Araki Y and Andoh A: Modification of intestinal flora in the treatment of inflammatory bowel disease. Curr Pharm Des 9: 333-346, 2003.
14. Manning AP, Heaton KW and Harvey RF: Wheat fibre and irritable bowel syndrome. A controlled trial. Lancet 2: 417-418, 1977.
15. Kassinen A, Krogius-Kurikka L, Makivuokko H, et al: The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 133: 24-33, 2007.
16. Madden JA and Hunter JO: A review of the role of the gut microflora in irritable bowel syndrome and the effects of probiotics. Br J Nutr 88 (suppl 1): 67-72, 2002.
17. Spiller R: Review article: probiotics and prebiotics in irritable bowel syndrome. Aliment Pharmacol Ther 28: 385-396, 2008.
18. Fukuda M, Kanauchi O, Araki Y, et al: Prebiotic treatment of experimental colitis with germinated barley foodstuff: a comparison with probiotic or antibiotic treatment. Int J Mol Med 9: 65-70, 2002.
19. Bouhnik Y, Pochart P, Marteau P, Arlet G, Goderel I and Rambaud JC: Fecal recovery in humans of viable Bifidobacterium sp ingested in fermented milk. Gastroenterology 102: 875-878, 1992.
20. Takahashi T, Nakade Y, Fukuda H, Tsukamoto K, Mantyh C and Pappas TN: Daily intake of high dietary fiber slows accelerated colonic transit induced by restrain stress in rats. Dig Dis Sci 53: 1271-1277, 2008.
21. Tanabe H, Sugiyama K, Matsuda T, Kiriyama S and Morita T: Small intestinal mucins are secreted in proportion to the settling volume in water of dietary indigestible components in rats. J Nutr 135: 2431-2437, 2005.
22. Hayashi K, Hara H, Asvarujanon P, Aoyama Y and Luangpituksa P: Ingestion of insoluble dietary fibre increased zinc and iron absorption and restored growth rate and zinc absorption suppressed by dietary phytate in rats. Br J Nutr 86: 443-451, 2001.
23. Kanauchi O, Mitsuyama K, Andoh A: Treatment of ulcerative colitis with germinated barley foodstuff and mechanism of butyrate production by microbiota in vitro. J Clin Biochem Nutr 43: 82-86, 2008.
24. Kanauchi O, Fujiyama Y, Mitsuyama K, et al: Increased growth of Bifidobacterium and Eubacterium by germinated barley foodstuff, accompanied by enhanced butyrate production in healthy volunteers. Int J Mol Med 3: 175-179, 1999.
25. Kanauchi O, Mitsuyama K, Andoh A and Iwanaga T: Modulation of intestinal environment by prebiotic germinated barley foodstuff prevents chemo-induced colonic carcinogenesis in rats. Oncol Rep 20: 793-801, 2008.
26. Kanauchi O, Serizawa I, Araki Y, et al: Germinated barley foodstuff, a prebiotic product, ameliorates inflammation of colitis through modulation of the enteric environment. J Gastroenterol 38: 134-141, 2003.
27. Torii A and Toda G: Management of irritable bowel syndrome. Intern Med 43: 353-359, 2004.
28. Saito T, Mizutani F, Iwanaga Y, Morikawa K and Kato H: Laxative and anti-diarrheal activity of polycarbophil in mice and rats. J Pharmacol 89: 133-141, 2002.
29. Miyata K, Kamato T, Nishida A, et al: Role of the serotonin3 receptor in stress-induced defecation. J Pharmacol Exp Ther 261: 297-303, 1992.
30. Ren TH, Wu J, Yew D, et al: Effects of neonatal maternal separation on neurochemical and sensory response to colonic distension in a rat model of irritable bowel syndrome. Am J Physiol 292: G849-G856, 2007.
31. Al-Chaer ED, Kawasaki M and Pasricha PJ: A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development. Gastroenterology 119: 1276-1285, 2000.
32. Bercik P, Wang L, Verdu EF, et al: Visceral hyperalgesia and intestinal dysmotility in a mouse model of postinfective gut dysfunction. Gastroenterology 127: 179-187, 2004.
33. Kanauchi O, Nakamura T, Agata K, Mitsuyama K and Iwanaga T: Effects of germinated barley foodstuff on dextran sulfate sodium-induced colitis in rats. J Gastroenterol 33: 179-188, 1998.
34. Spangeus A and El-Salhy M: Large intestinal endocrine cells in non-obese diabetic mice. J Diabetes Complications 12: 321-327, 1998.
35. Kobayashi S, Ikeda K, Suzuki M, Yamada T and Miyata K: Effects of YM905, a novel muscarinic M3-receptor antagonist, on experimental models of bowel dysfunction in vivo. J Pharmacol 86: 281-288, 2001.
36. Ness TJ and Gebhart GF: Colorectal distension as a noxious visceral stimulus: physiologic and pharmacologic characterization of pseudaffective reflexes in the rat. Brain Res 450: 153-169, 1988.
37. Drzikova B, Dongowski G and Gebhardt E: Dietary fibre-rich oatbased products affect serum lipids, microbiota, formation of shortchain fatty acids and steroids in rats. Br J Nutr 94: 1012-1025, 2005.
38. Spiller R: Serotonin and GI clinical disorders. Neuropharmacology 55: 1072-1080, 2008.
39. Squires PE, Rumsey RD, Edwards CA and Read NW: Effect of short-chain fatty acids on contractile activity and fluid flow in rat colon in vitro. Am J Physiol 262: G813-G817, 1992.
40. Coates MD, Mahoney CR, Linden DR, et al: Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 126: 1657-1664, 2004.
41. Fukumoto S, Tatewaki M, Yamada T, et al: Short-chain fatty acids stimulate colonic transit via intraluminal 5-HT release in rats. Am J Physiol Regul Integr Comp Physiol 284: R1269-R1276, 2003.
42. Rousseaux C, Thuru X, Gelot A, et al: Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med 13: 35-37, 2007.
43. Snook J and Shepherd HA: Bran supplementation in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 8: 511-514, 1994.
44. Yamada T, Kitayama M, Yamazaki M, Nagata O, Tamaj I and Tsuji A: Physicochemical properties of calcium polycarbophil, a water-absorbing polymer. J Pharm Pharmacol 48: 665-668, 1996.
45. Collins SM, Barbara G and Vallance B: Stress, inflammation and the irritable bowel syndrome. Can J Gastroenterol 13: A47-A49, 1999.
46. Kanauchi O, Mitsuyama K and Andoh A: The therapeutic impact of manipulating microbiota in inflammatory bowel disease. Curr Pharm Des 15: 2074-2086, 2009.